Related Experiment Video
Updated: Apr 13, 2026

28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
34.4K
Decennial Analysis of Interventional Left Atrial Appendage Closure
Boris Schmidt1, Stefano Bordignon1, Alexander Fuernkranz1
1Cardioangiologisches Centrum Bethanien, Frankfurt/M., Germany.
Journal of Cardiovascular Electrophysiology
|May 2, 2015
Summary
Long-term follow-up after left atrial appendage closure (LAAC) in nonvalvular atrial fibrillation (AF) patients shows low rates of thrombotic and bleeding events. This first-generation device demonstrated favorable outcomes during extended monitoring.
Area of Science:
- Cardiology
- Interventional Cardiology
- Electrophysiology
Background:
- Limited long-term follow-up (LTFU) data exists for interventional left atrial appendage closure (LAAC) in nonvalvular atrial fibrillation (AF) patients.
- Assessing outcomes with first-generation LAAC devices is crucial for understanding long-term safety and efficacy.
Purpose of the Study:
- To evaluate the long-term outcomes of patients undergoing LAAC using a first-generation device.
- To determine the rates of thrombotic and bleeding complications after LAAC in a nonvalvular AF population.
Main Methods:
- Analysis of the Cardioangiologisches Centrum Bethanien (CCB) LAAC registry database.
- Inclusion of 45 AF patients who received LAAC between October 2001 and July 2007.
- Post-implant dual-platelet inhibition followed by aspirin indefinitely; median follow-up of 7.4 years.
Main Results:
- The observed annual stroke rate was 1.7% (RR 0.43, P = 0.0028), and the annual bleeding rate was 2.1% (RR 0.56, P < 0.0001).
- No deaths were attributed to stroke or bleeding complications.
- Fourteen patients died, primarily from heart failure or non-cardiac causes.
Conclusions:
- LAAC with first-generation devices in nonvalvular AF patients is associated with lower-than-expected rates of thrombotic and bleeding complications during long-term follow-up.
- These findings support the safety and efficacy of LAAC for stroke risk reduction in AF patients.

